World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Drug Companies Face Political, Scientific Attacks
Keywords:
Tags:
Just as the drug industry is more getting more dependent on the government with the medicare drug benefit raising the retail drug purchases paid by government to 34% in 2006 from 28% in 2005, the industry is facing more governmental scrutiny, from the FDA, from Congress from the public, and during this election campaign. Rep .Rosa DeLauro, who heads the House appropriations subcommittee that has oversight over FDA funding compares the drug industry to the tobacco industry saying that it requires the same amount of scrutiny. At the same time the drug industry is aware of the changes in the public mood and the recent controversies over drug studies, such as the one on Vytorin and other controversy. It is initiating some voluntary changes, registering clinical trial results, submitting commercials to the FDA before they air, and under pressure from medical journals registering trials before they are performed. A new law will requires and its not clear whether the drug industry is dragging its feet and then making changes when there is increasing public pressure. This is the feeling of the medical journals like the Journal of the Medical Association and the New England Journal of Medicine. JAMA's editors will be keeping up this pressure as they have more articles showing how the drug industry manipulates data and the need for public skepticism of information that comes out of the drug industry. The New England Journal editors expressed the need to publish information that helps doctors get all the available information, and not just the information from the drug industry that makes the drug look better than it really is, such as the information and analysis it provided on antidepressant medications. The chairman of the energy and commerce investigations subcommittee Rep. Stupak, finds the advertising for drugs contains information that cannot be backed up and not true ethically, medically, or legally. As this reflects the public mood look for more investigations in Congress and investigative research by the journals. On the issue of importation of drugs from Canada there is bipartisan support as both Senator McCain and Senator Clinton support importation. Clinton supports legislation that allows the FDA to approve new generic versions of biotech drugs which would lower prices of biotech drugs. And with the US consumer budget facing strains in a recession there will be increasing pressure and demands for relief in the area of drug prices, especially for the elderly and uninsured and from corporate payors.
Slimming down marketing and sales at American and European pharmaceutical companies.
10/25/2006
American and European drug companies are slimming down marketing and sales as the old marketing practices are not working, and new strategies are taking their place.
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
Wall Street Journal 01/16/2007
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
CEO Gambles on a Novartis Makeover
Wall Street Journal 05/20/2008
Drug Industry to Announce Revised Code on Marketing
New York Times 07/10/2008
Wall Street Journal 10/21/2008
FDA and the drug safety, production and marketing practices of pharmaceutical companies.
07/01/2005
The increasing controversy surrounding the safety and marketing of many pharmaceutical products and the role of the FDA in ensuring safe use and avoiding risks to users.
Grouped Articles
New F.D.A.: Transparence and Flexibility
New York Times 09/24/2010
FDA Plan Would Aid Drug Makers in Liability Suits
Wall Street Journal 01/14/2006
FDA Moves Toward Harder Line on Suicide Risks
Wall Street Journal 07/01/2005
Baxter Infusion Pumps Are Target of FDA Probe
Wall Street Journal 07/22/2005
Financial Ties to Industry Cloud Major Depression Study
Wall Street Journal 07/11/2006
Avandia Concerns Reopen a Wider Debate
Wall Street Journal 05/23/2007
Pharmaceutical companies' advertising of drugs to consumers.
08/03/2005
The advertising efforts and budgets of pharmaceutical companies and the risks to consumers of improper advertising.
Grouped Articles
Drug Makers to Police Consumer Campaigns
New York Times 08/03/2005
Glaxo to Weigh Results Of New Diet Pill
Wall Street Journal 10/24/2007
Putting Drug Ads Back In The Bottle
BusinessWeek 08/13/2007
Making a Name for Drugs Without Using Their Names
Wall Street Journal 08/29/2008
Drug Makers, Facing Critics, Will Stop Some Ads
Wall Street Journal 12/11/2008
Drug Firms' Spending on Consumer Ads Fell 8% in '08, a Rare Marketing Pullback
Wall Street Journal 04/16/2009
Anemia drug marketing practices
04/10/2007
Grouped Articles
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
Amgen Told to Reword Drug Label
New York Times 07/31/2008
FDA Cancer Czar Stirs Debate On Agency's Role
Wall Street Journal 03/12/2008
Stronger Warnings on 3 Drugs for Anemia
New York Times 11/09/2007
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Digital Tools and marketing in the Pharmaceutical Industry
10/25/2006
How drug makers are using websites, the internet and digital tools to reshape marketing and reduce the number of salespeople.
Grouped Articles
Drug Makers Replace Reps With Digital Tools
Wall Street Journal 05/10/2011
Drug Reps Soften Their Sales Pitches
Wall Street Journal 01/10/2012
How Glaxo Marketed a Malady to Sell a Drug - WSJ.com
Wall Street Journal 10/25/2006
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
J&J and the settlement with the U.S. Justice Department for off-label marketing of drug Risperdal
04/10/2007
Grouped Articles
Johnson & Johnson to Pay $2.2 Billion to Settle U.S. Probes
Wall Street Journal 11/05/2013
J&J Close to Settling Off-Label Probes
Wall Street Journal 06/21/2012
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
FDA Cancer Czar Stirs Debate On Agency's Role
Wall Street Journal 03/12/2008
Stronger Warnings on 3 Drugs for Anemia
New York Times 11/09/2007
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Vytorin study and the controversy over drug company marketing and pricing tactics.
12/17/2007
Merck sells Vytorin a combination of Zocor and Zetia for a expensive price touting benefits that may not exist according to its own study when generic Zocor can be bought for $6 for 30 days supply.
Grouped Articles
Stakes Remain High in Merck, Schering-Plough Drug Study
Wall Street Journal 12/17/2007
Drug Has No Benefit in Trial, Makers Say
New York Times 01/14/2008
Study Missteps Threaten Turnaround at Schering
Wall Street Journal 01/17/2008
Heart Group Backs Drug Made by Ally
New York Times 01/24/2008
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
The struggle to get legislation passed to allow importation of drugs.
01/23/2008
Failure of the Byron Dorgan legislation by 9 votes in the Senate even thogh a coalition of Democrats and Republicans support it, with the Obama Administration opposing it. President Obama turns his back on action that he supported to help Americans hurt hig prescription costs, after pharmaceutial industry lobbyists are able to influence the Obama administration. Just as in the banking industry the Obama adminsitration is letting lobbyists influence its policies.
Grouped Articles
President Obama writes a new health reform prescription
Washington Post 12/16/2009
Wall Street’s resurgent prosperity frustrates its claims, and Obama’s - The Washington Post
Washington Post 11/07/2011
What caused the financial crisis? The Big Lie goes viral - The Washington Post
Washington Post 11/07/2011
A grim diagnosis for our ailing U.S. health care system - The Washington Post
Washington Post 11/28/2011
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
White House visitor logs show lobbying going strong - The Washington Post
Washington Post 05/21/2012
Safety and marketing issues raised about drugs generating large sales for pharmaceutical companies.
10/25/2006
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
Medical Journal Spikes Article On Industry Ties Of Kidney Group - WSJ.com
Wall Street Journal 12/26/2006
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Suit Details How J&J Pushed Sales of Procrit
Wall Street Journal 05/10/2007
BusinessWeek 05/21/2007
Sequel for Vioxx Critic: Attack on Diabetes Pill
Wall Street Journal 05/22/2007
Large legal settlements in the pharmaceutical industry.
10/25/2006
The settlements also involve drug pricing and marketing.
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
In Guilty Plea, OxyContin Maker to Pay $600 Million
New York Times 05/10/2007
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Drug Industry to Announce Revised Code on Marketing
New York Times 07/10/2008
Drug Approval Is Not a Shield From Lawsuits, Justices Rule
New York Times 03/05/2009
Abbott Labs's $1.6 billion legal settlement for aggressive marketing of neurologic drug Depakote in U.S. nursing homes
04/10/2007
Grouped Articles
Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote - The Washington Post
Washington Post 05/08/2012
Abbott to Pay $1.6 Billion Over Illegal Marketing
New York Times 05/07/2012
Wall Street Journal 05/08/2012
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
FDA Cancer Czar Stirs Debate On Agency's Role
Wall Street Journal 03/12/2008
Stronger Warnings on 3 Drugs for Anemia
New York Times 11/09/2007
Changing marketing landscape for Drug Companies
10/02/2006
Controversial practices of some companies, Changes in the marketing strategies and practices of companies like Pfizer.
Grouped Articles
Glaxo Epilepsy Drug Is Linked to Defects Found in Newborns - WSJ.com
Wall Street Journal 10/02/2006
How Glaxo Marketed a Malady to Sell a Drug - WSJ.com
Wall Street Journal 10/25/2006
Pfizer to Cut 20% Of U.S. Sales Force, Signaling End of Era - WSJ.com
Wall Street Journal 11/29/2006
AstraZeneca Vows to Work With FDA - WSJ.com
Wall Street Journal 11/28/2006
Cephalon Used Improper Tactics To Sell Drug, Probe Finds - WSJ.com
Wall Street Journal 11/21/2006
Taking Risk for Profit, Industry Seeks Cancer Drugs
New York Times 09/02/2009
Glaxo's settlement for aggressive marketing and its overhaul of its marketing effort.
04/10/2007
A $400 million settlement for off-label promotion of Paxil and Wellbutrin antidepressant drugs.
Grouped Articles
GlaxoSmithKline Probes Bribe Allegations in China
Wall Street Journal 06/12/2013
Glaxo Names New China Chief Amid Bribery Probe
Wall Street Journal 07/26/2013
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
Glaxo Braces for Probes, Hires FDA Ex-Litigator
Wall Street Journal 07/23/2008
Glaxo Plans 12% Reduction in Its U.S. Drug Sales Force
Wall Street Journal 11/06/2008
Novartis Trileptal drug marketing legal settlement for $185 million
01/23/2008
Grouped Articles
U.S. Accuses Novartis of Kickbacks
Wall Street Journal 04/28/2013
Novartis Case Underscores Increased Scrutiny of Drug Marketing
Wall Street Journal 01/29/2010
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Novartis is developing a whole new system for developing pharmaceutical treatments by putting medical science at the centre of things.
12/11/2007
Novartis' CEO Vasella, and Dr Fishman who heads the global research labs in Cambridge, Massachusetts, are redoing the way the company develops drugs and runs the company. Senior leaders are now medically trained scientists, and Novartis has shed much of the old marketing and sales staff. Drug discovery focusses on Dr. Fishman's approach to go after common molecular pathways and develop medicines for diseases that may be rare, but reveal the knowledge behind addressing all diseases that have that common underlying molecular pathway as the source of the diseases functioning.
Grouped Articles
Novartis Chairman Stresses Need for R&D Investment
Wall Street Journal 03/22/2014
Wall Street Journal 12/11/2007
Wall Street Journal 12/17/2007
BusinessWeek 05/08/2008
CEO Gambles on a Novartis Makeover
Wall Street Journal 05/20/2008
BusinessWeek 09/04/2008
Increasing scruiny in the pharmaceutical industry
05/29/2007
Drug companies come under intense scrutiny with a chairperson of a House Committe with FDA funding oversight comparing the drug industry to the tobacco industry. Scrutiny from medical journals, congress, the media and public of controversial pricing practices, advertising, and presentation of internal study findings.
Linked Articles
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Wall Street Journal 05/29/2007
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
